AstraZeneca Pharma India Beheer
Beheer criteriumcontroles 1/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Sanjeev Panchal
Algemeen directeur
₹38.7m
Totale compensatie
| Percentage CEO-salaris | 83.4% |
| Dienstverband CEO | 1.8yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 1.3yrs |
| Gemiddelde ambtstermijn bestuur | less than a year |
Recente managementupdates
Recent updates
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors
Sep 18
We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability
Jun 03Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S
May 22We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease
Apr 04Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Nov 10AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00
Jul 06Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Jun 16Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
Aug 02Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock
Feb 25Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Feb 04Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Jan 18
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years
Dec 31We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability
Dec 13Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching
Nov 25Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay
Nov 07What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Oct 20AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Sep 24If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today
Aug 28What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?
Aug 02Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Jul 12Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹959m |
| Mar 31 2024 | ₹39m | ₹32m | ₹2b |
| Dec 31 2023 | n/a | n/a | ₹1b |
| Sep 30 2023 | n/a | n/a | ₹2b |
| Jun 30 2023 | n/a | n/a | ₹1b |
| Mar 31 2023 | ₹21m | ₹5m | ₹993m |
Compensatie versus markt: De totale vergoeding ($USD 459.01K ) Sanjeev } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 479.87K ).
Compensatie versus inkomsten: De beloning van Sanjeev is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.
CEO
Sanjeev Panchal (47 yo)
1.8yrs
Tenure
₹38,725,314
Compensatie
Dr. Sanjeev Kumar Panchal serves as Country President of AstraZeneca Pharma India Limited since January 01, 2023 and serves as its Managing Director since January 01, 2023. He serves as Director of AstraZe...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD, Country President & Director | 1.8yrs | ₹38.73m | geen gegevens | |
| Whole-Time Director & CFO | 1.1yrs | ₹30.59m | geen gegevens | |
| Legal Counsel | 7.8yrs | ₹3.73m | geen gegevens | |
| Company Secretary & Compliance Officer | 2.3yrs | geen gegevens | geen gegevens | |
| Vice President of Human Resources | no data | ₹12.28m | geen gegevens | |
| Interim Business Unit Head of Oncology & Director of Commercial Excellence | 1.3yrs | geen gegevens | geen gegevens | |
| Head of Oncology Business Unit | less than a year | geen gegevens | geen gegevens | |
| Business Unit Head - Rare Disease unit | less than a year | geen gegevens | geen gegevens | |
| Legal Head | no data | geen gegevens | geen gegevens |
1.3yrs
Gemiddelde duur
Ervaren management: Het managementteam van ASTRAZEN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD, Country President & Director | 1.8yrs | ₹38.73m | geen gegevens | |
| Whole-Time Director & CFO | less than a year | ₹30.59m | geen gegevens | |
| Independent Non-Executive Director | 7.9yrs | ₹1.20m | geen gegevens | |
| Additional Independent Director | less than a year | geen gegevens | geen gegevens | |
| Additional Non-Executive Director | less than a year | geen gegevens | geen gegevens | |
| Independent Non-Executive Chairperson of the Board | 2.9yrs | ₹1.30m | geen gegevens | |
| Non-Executive Director | less than a year | geen gegevens | geen gegevens |
1.0yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ASTRAZEN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1 jaar), wat duidt op een nieuw bestuur.